On Sunday, October 15th, Dr. David Samati hosted another successful Livestream on his web show, “Sunday Housecall.” Every Sunday browse to his website, Samaditiv.com, every Sunday at 12:30 pm EDT to hear the Chief of Robotic Surgery and Chairman of Urology at New York City’s Lennox Hill hospital offer his professional input and experience on the world of medicine today. Recently, Dr. Samadi interviewed Dr. Cynara Cooper, Northwell Health Staten Island University Hospital’s Chief of Breast Surgery.
“October is Breast Cancer Awareness Month, and I thought who better to interview than Dr. CynaraCoomer, one of the primary catalysts in establishing the first Comprehensive Breast Center on Staten Island,” says Dr. Samadi in an introduction . “… [she is] one of the foremost experts in breast health.”
Dr. Coomer formally operated a successful practice in Mt. Sinai before taking on the esteemed position she holds today and puled from her vast medical experience to help Dr. Samadi educate the audience on important women’s health issues. She made sure not only to give a thorough review of on issues of the breast with Dr. Samadi but also to inform on prostate issues to educate the men as well as the women on their on their health.
Dr. Samadi is himself no stranger to the prostate. He built his career as a urologic oncologist trained in robotic surgery. With the use of robotics and the latest technology, Dr. Samadi offers minimally invasive treatments for prostate cancer, with laparoscopic radical prostatectomy and laparoscopic robotic radical prostatectomy being among the procedures he performs. Outside of the operating table, Dr. Samadi works towards recognizing cancer before becomes malignant and plays a key role in the training of surgeons and urologists to spread his well-regarded professionalism and technique to others. He particularly well regarded for the outstanding success of the SMART Surgery he pioneered. His resume includes work towards the early diagnostic treatment of malignant prostate cancer, and he is one of the only urologic surgeons in the United States trained in oncology, open, laparoscopic, and robotic surgery.
Be sure to check in next Sunday for the next interview or solo discussion by Dr. David Samaidi on Sunday Housecall! Don’t forget! The live-stream starts at 12:30 pm EDT on Samaditv.com.
Read More: www.huffingtonpost.com/author/dr-david-samadi
Founder, President, CEO, and Chairman of the Board of Seattle Genetics, Dr. Clay Siegall is a man of many accomplishments. One may wonder how a Zoology student landed in the cancer research business, but as he tells Inspirery, the answer is a highly personal one. “A family member got sick and the treatment regimen was just brutal.” He shares that this family member nearly died from the chemotherapy treatment, not the cancer. When asked what makes Seattle Genetics successful, Seigall attributes it all to hard work, passion and inordinate amounts of focus.
Siegall obtained his Bachelor of Science degree in Zoology from the University of Maryland and his Ph. D in Genetics from George Washington University. His professional experience includes Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health, National Cancer Institute. He is the author of over 70 publications, holds 15 patents, and was recognized by his alma mater, the University of Maryland in 2013 as the Alumnus of the Year for Computer, Math and Natural Sciences. He also sits on the Board of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable.
Dr. Clay Siegall founded Seattle Genetics in 1998. This global company is located in the Pacific Northwest of the U.S. focused on oncology biotechnology. Simply stated, they are in the business of transforming cancer treatment as we know it, through the creation of and making cancer treatment drugs available that are more effective and less detrimental on the patient. Their primary product is called Adcetris and treats Hodgkin lymphoma relapses as well as relapsed systemic anaplastic large cell lymphoma.
Clay is focused on innovating cancer treatment and is passionate about helping suffering from cancer, and he is good at what he does. He blogs regularly about the fight against cancer and admittedly shares about the stresses of starting a new company, but his persistence and passion saw Seattle Genetics through from challenging times to success. Admirably he doesn’t take all of the credit, publicly thanking the geneticists and sales members of his team for where his company is today.
Clay B. Siegall is a prominent scientist who has played an integral role in conducting extensive research that seeks to develop cancer treatments. Through Seattle Genetics, he has made major contributions in the field of cancer therapy. Clay co-founded the biotechnology company in 1998. His passion for helping cancer patients was inspired by firsthand experience. His father was diagnosed with cancer and later on, died from complications of the disease. His dad’s ailment made him realize the shortage of oncology resources, which motivated him to venture into genetics. He sought to initiate many changes in the field of oncology. Dr. Clay is highly committed to his objective of bringing relief to cancer patients through developing cancer therapies. His enthusiasm has seen Seattle Genetics come up with products that prolong the lives of cancer patients. He believes that gaining knowledge in different fields is significant in aiding one to achieve his or her entrepreneurial goals. Clay attributes the firm’s success to their business strategy of collaborating with other companies in the industry, thus enhancing their research. This information was originally mentioned on Ideamensch as outlined in this link https://ideamensch.com/clay-b-siegall/
About Clay B. Siegall
Clay B. Siegall, PhD, serves as the president, CEO and chairman of Seattle Genetics. The company is a leader in the development of antibody-drug conjugates (ADCs). He employs a blend of extensive research, drug development practices and his undying desire to help others to provide the company with visionary leadership. Clay played an instrumental role in ensuring that FDA approves their first ADC, ADCETRIS, in 2011. The company has collaborated with Takeda Pharmaceutical Company to sell the drug in more than 65 countries. Dr. Siegall looks forward to ensuring that ADCETRIS is approved in many countries. He has also partnered with various companies to enhance their ADC technology.
Siegall studied genetics at the celebrated George Washington University where he earned his PhD. He is also an alumnus of the University of Maryland where he graduated with his B.S. in zoology. Previously, Clay worked for Bristol-Myers Squibb Pharmaceutical Research Institute before joining the National Cancer Institute and the National Institutes of Health. He is an active board member of Ultragenyx Pharmaceutical, Washington Roundtable and Alder BioPharmaceuticals. Clay is a proud recipient of the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. Siegall has written many articles, which have been published in different journals. He holds 15 patents.